Celsion receives NIH SBIR grant to develop heat sensitive liposomal technology for cancer treatment
Celsion receives NIH SBIR grant to develop heat sensitive liposomal technology for cancer treatment
Celsion Corporation, a biotechnology drug development company, announced today that it has been awarded a competitive Phase I Small Business Innovation and Research (SBIR) grant from the National Institutes of Health (NIH), to support the proposal, “New Thermal Sensitive Carboplatin Liposomes for Cancer”.
Read more on News-Medical-Net
Categories: Breast Cancer Treatment Tags: cancer, Celsion, develop, grant, heat, liposomal, receives, SBIR, sensitive, technology, Treatment
Celsion Receives Fast Track Designation For ThermoDox® Development Program To Treat Primary Liver Cancer
Celsion Receives Fast Track Designation For ThermoDox® Development Program To Treat Primary Liver Cancer
Celsion Corporation (Nasdaq: CLSN ), a leading oncology drug development company, today announced that the U.S. Food and Drug Administration (FDA) has designated the HEAT Study of its investigational drug, ThermoDox®, in combination with radiofrequency ablation (RFA), as a Fast Track Development Program.
Read more on PharmaceuticalOnline
Categories: Breast Cancer Risks Tags: cancer, Celsion, Designation, Development, fast, liver, Primary, program, receives, ThermoDox®, track, treat
Celsion announces presentation of long-term follow-up data from Phase I ThermoDox dose escalation trial
Celsion announces presentation of long-term follow-up data from Phase I ThermoDox dose escalation trial
Celsion Corporation today announced that Dr. Ronnie T.P. Poon, a principal investigator of the Phase I ThermoDox® dose escalation trial, held a press conference at the University of Hong Kong to provide an update on the long-term follow-up data from patients treated at his center as well as present illustrative patient case studies. The Phase I trial was conducted in 2006.
Read more on News-Medical-Net
Categories: Breast Cancer Research Tags: Announces, Celsion, Data, Dose, escalation, FollowUp, From, LongTerm, Phase, Presentation, ThermoDox, Trial
Celsion Announces Long-Term Follow-Up Data From Phase 1 ThermoDox(R) Trial is Presented at the University of Hong Kong …
Celsion Announces Long-Term Follow-Up Data From Phase 1 ThermoDox(R) Trial is Presented at the University of Hong Kong …
Celsion Corporation today announced that Dr. Ronnie T.P. Poon, a principal investigator of the Phase I ThermoDox® dose escalation trial, held a press conference at the University of Hong Kong to provide an update on the long-term follow-up data from patients treated at his center as well as present illustrative patient case studies.  The Phase I trial was conducted in 2006.  A presentation of …
Read more on PR Newswire via Yahoo! Finance
Categories: Breast Cancer Research Tags: Announces, Celsion, Data, FollowUp, From, Hong, Kong, LongTerm, Phase, presented, ThermoDoxR, Trial, University
Celsion Corporation Announces ThermoDox(R) Abstract Accepted for Presentation at the American Society of Clinical …
Celsion Corporation Announces ThermoDox(R) Abstract Accepted for Presentation at the American Society of Clinical …
Celsion Corporation today announced that an abstract about the Phase I/II trial of ThermoDox® in Recurrent Chest Wall Cancer has been accepted for presentation at the American Society of Clinical Oncology 2010 Annual Meeting.  The abstract presents the background, rationale, and design of the DIGNITY study which is ongoing and evaluating ThermoDox in combination with hyperthermia in women with …
Read more on PR Newswire via Yahoo! Finance
Categories: Breast Cancer Research Tags: Abstract, Accepted, American, Announces, Celsion, Clinical, Corporation, Presentation, society, ThermoDoxR